The prevalence of bone diseases is rising worldwide as the aging population of individuals who are 55+ continues to grow. This has led to an increasing demand for Bone Graft Substitutes (BGS) to support bone repair and regeneration. BGS is a surgical procedure in which the damaged bone is replaced with a piece of bone that is taken from another part of the patient’s body. As a result, Platelet-rich plasma (PRP) and Bone Marrow Aspirate Concentrate (BMAC) are both growing in the cell therapy market as they are used as complements for BGS to assist in the healing process.
PRP and BMAC are both regenerative therapies that utilize a concentration that is extracted from the patient to promote healing and tissue regeneration. Aiming to stimulate the body’s natural healing process, providing bone grafting the structural support with external bone material. With its regenerative capabilities, low risks of complications, and continuous education on stem cell therapy, it has caused the cell therapy market to grow over $550 million in 2024, with an expected increase over the forecast period at a compound annual growth rate of roughly 7% from 2025 to 2031. The trend is expected to grow further past the forecast after considering the potential it has in the sports medication market and the expansion of its clinical application for standardization of treatment in other areas.
Benefits of Platelet-Rich Plasma and Bone Marrow Aspirate Concentrate
PRP and BMAC have several benefits for bone grafting, which is why they are used often together. Some of these benefits are:
Minimally Invasive – Both of the procedures use a needle-based extraction and injection, avoiding the need for major surgery application.
Autologous – Due to the PRP and BMAC being acquired from the patient’s body, risks of rejection, allergic reactions, or disease transmission are low.
Reduces Pain and Inflammation – These procedures are commonly used to manage chronic pain, meaning that they can assist with pain management.
Shorter Recovery Times – Patients often experience faster healing and return to activity compared to those undergoing traditional surgical procedures.
Although PRP is a strong supporter for bone grafting, future bone marrow stem cell products are likely to be based on current BMAC technology, as stem cell isolation and expansion are costly processes. BMAC has great potential for bone repair and regeneration over platelet-rich plasma and will predominate in the future of spinal fusion surgery.
Market Leaders in Cell Therapy
In 2024, Terumo was the leader of the orthopedic cell therapy market with its Harvest Technologies product line. This includes Harvest® BMAC and Harvest® PRP, as well as the Harvest® AdiPrep® adipose tissue concentrator. Additionally, its Harvest® SmartPrep® multicellular processing system is a versatile device capable of concentrating bone marrow, blood, and adipose tissue for therapeutic applications.
Zimmer Biomet held the second-leading position, offering Plasmax® plasma concentration and decompression system along with the BioCUE™ System, which can process both bone marrow and whole blood for regenerative treatments.
Arthrex ranked third in the market, with its Arthrex Angel® cPRP and Bone Marrow Processing System serving as a key product. This advanced system is designed to efficiently concentrate platelet-rich plasma (PRP) and bone marrow aspirate (BMA), making it particularly effective for orthopedic and soft tissue treatments. It features cutting-edge sensor technology, automating the separation and concentration of blood components with minimal manual handling.
Future Outlook of the PRP and BMAC Markets
As regenerative medicine continues to evolve, the demand for biologic-based therapies like PRP and BMAC is expected to grow. Advances in cell processing technologies and biomaterial integration may further enhance their effectiveness, making them more widely adopted across orthopedic and spinal fusion treatments. While platelet-rich plasma remains a valuable option for soft tissue healing, bone marrow aspirate concentrate is poised to become the dominant choice for bone regeneration due to its higher stem cell concentration. As research progresses, future innovations may focus on improving stem cell isolation techniques and expanding clinical applications beyond orthopedics, solidifying PRP and BMAC as essential tools in regenerative medicine.
To learn more about the Global Orthopedic Cell Therapy Market and Global Orthopedic Bone Graft Substitute Market, refer to our recently released 2025 reports.
